. Aasld/idsa-hcv-guidance and . Panel, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, vol.62, pp.932-54, 2015.

, European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016, J Hepatol, vol.66, pp.153-94, 2017.

O. El-sherif, S. Khoo, and C. Solas, Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection, Curr Opin HIV AIDS, vol.10, pp.348-54, 2015.

. European-medicines-agency and . Harvoni, Summary of Product characteristics, p.13, 2017.

P. German, P. S. Pang, L. Fang, D. Chung, and A. Mathias, Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir, Hepatology, vol.60, issue.1, p.1976, 2014.

P. German, P. Pang, S. West, L. Han, K. Sajwani et al., Drug interactions between direct-acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract O_06, Presented at: 15 th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 2014.

K. Garrisson, J. Custodio, P. Pang, M. Das, F. Cheng et al., Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens

, 16 th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 2015.

S. Rodríguez-nóvoa, P. Labarga, A. Barreiroa, P. Albalatec, M. Vispo et al., Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations, AIDS, vol.24, pp.1064-1070, 2010.

M. Ezinga, J. Wetzels, M. Bosch, A. J. Van-der-ven, and D. M. Burger,

, Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration, Antivir Ther, vol.19, pp.765-71, 2014.

I. Poizot-martin, C. Solas, J. Allemand, V. Obry-roguet, V. Pradel et al., Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration, J Acquir Immune Defic Syndr, vol.62, pp.375-80, 2013.

P. Pugliese, L. Cuzin, A. Cabié, I. Poizot-martin, C. Allavena et al., A large French prospective cohort of HIV-infected patients: the Nadis cohort, HIV Med, vol.10, pp.504-515, 2009.

M. J. Goolsby, National Kidney Foundation guidelines for chronic kidney disease: evaluation, classification, and stratification, J Am Acad Nurse Pract, vol.14, pp.238-280, 2002.

C. Southan, J. L. Sharman, H. E. Benson, E. Faccenda, A. J. Pawson et al., The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands, Nucl Acids Res, vol.44, pp.1054-68, 2016.

S. Alexander, E. Kelly, N. Marrion, J. A. Peters, H. E. Benson et al., The concise guide to PHARMACOLOGY 2015/16: transporters, Br J Pharmacol, vol.172, pp.6110-202, 2015.

. European-medicines-agency and . Viread, Summary of Product characteristics, p.5, 2017.

A. S. Ray, T. Cihlar, K. L. Robinson, L. Tong, J. E. Vela et al., Mechanism of active renal tubular efflux of tenofovir, Antimicrob Agents Chemother, vol.50, pp.3297-304, 2006.

B. Fernandez-fernandez, A. Montoya-ferrer, A. B. Sanz, M. D. Sancheznino, M. C. Izquierdo et al., Tenofovir nephrotoxicity: 2011 update, AIDS Res Treat, 2011.

B. Schaaf, S. P. Aries, E. Kramme, J. Steinhoff, and K. Dalhoff, Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome, Clin Infect Dis, vol.37, pp.41-44, 2003.

A. E. Zimmermann, T. Pizzoferrato, J. Bedford, A. Morris, R. Hoffman et al., Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions, Clin Infect Dis, vol.42, pp.283-90, 2006.

S. M. Baxi, R. M. Greenblatt, P. Bacchetti, R. Scherzer, H. Minkoff et al., Common clinical conditions -age, low BMI, ritonavir use, mild renal impairment -affect tenofovir pharmacokinetics in a large cohort of HIV-infected women, AIDS, vol.28, pp.59-66, 2014.

P. Morlat, Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'experts, Ministère des affaires sociales et de la Santé. Conseil national du Sida. Agence nationale de recherches sur le sida et les hépatites virales. Rapport, 2013.

M. J. Vivancos-gallego, A. Moreno, M. J. Pérez-elias, C. Quereda, and D. ,

D. Santiago, A. Casado, and J. L. , Real-life renal safety of "boosted TDF, Presented at: 23 rd Conference on Retroviruses and Opportunistic Infections

, Boston, 2016.

K. L. Bunnell, S. Vibhakar, R. C. Glowacki, M. A. Gallagher, A. M. Osei et al., Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection, Pharmacotherapy, vol.36, pp.148-53, 2016.

J. E. Gallant, E. S. Daar, F. Raffi, C. Brinson, P. Ruane et al., Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial, Lancet HIV, vol.3, pp.158-65, 2016.

A. Pozniak, J. R. Arribas, J. Gathe, S. K. Gupta, F. A. Post et al., Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a singlearm, multicenter, open-label phase 3 study, J Acquir Immune Defic Syndr, vol.71, pp.530-537, 2016.

E. Mogalian, L. M. Stamm, A. Osinusi, G. Shen, K. Sajwani et al., Drug interaction studies between sofosbuvir/velpatasvir and boosted HIV ARV regimens, Presented at: 23 rd Conference on Retroviruses and Opportunistic Infections, 2016.